Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C.
Marwan G FakihLisa SalvatoreTaito EsakiDominik P ModestDavid P Lopez-BravoJulien TaiebMichalis V KaramouzisErika Ruiz-GarciaTae-Won KimYasutoshi KubokiFausto MeriggiDavid CunninghamKun-Huei YehEmily ChanJoseph ChaoYaneth SaportasQui TranChiara CremoliniFilippo PietrantonioPublished in: The New England journal of medicine (2023)
In this phase 3 trial of a KRAS G12C inhibitor plus an EGFR inhibitor in patients with chemorefractory metastatic colorectal cancer, both doses of sotorasib in combination with panitumumab resulted in longer progression-free survival than standard treatment. Toxic effects were as expected for either agent alone and resulted in few discontinuations of treatment. (Funded by Amgen; CodeBreaK 300 ClinicalTrials.gov number, NCT05198934.).